Senzime AB
Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive … Read more
Market Cap & Net Worth: Senzime AB (SEZI)
Senzime AB (ST:SEZI) has a market capitalization of $61.10 Million (Skr685.46 Million) as of March 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #21249 globally and #235 in its home market, demonstrating a -9.07% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Senzime AB's stock price Skr4.36 by its total outstanding shares 157215046 (157.22 Million).
Senzime AB Market Cap History: 2015 to 2026
Senzime AB's market capitalization history from 2015 to 2026. Data shows growth from $53.44 Million to $61.10 Million (0.78% CAGR).
Senzime AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Senzime AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.73x
Senzime AB's market cap is 0.73 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $92.82 Million | $1.63 Million | -$9.41 Million | 57.01x | N/A |
| 2017 | $99.50 Million | $189.00K | -$13.03 Million | 526.47x | N/A |
| 2018 | $105.11 Million | $3.21 Million | -$25.62 Million | 32.70x | N/A |
| 2019 | $255.06 Million | $6.71 Million | -$33.67 Million | 38.01x | N/A |
| 2020 | $336.34 Million | $9.34 Million | -$47.45 Million | 36.02x | N/A |
| 2021 | $319.53 Million | $10.98 Million | -$82.14 Million | 29.10x | N/A |
| 2022 | $150.51 Million | $14.03 Million | -$132.70 Million | 10.72x | N/A |
| 2023 | $104.13 Million | $35.75 Million | -$134.15 Million | 2.91x | N/A |
| 2024 | $77.08 Million | $58.48 Million | -$118.73 Million | 1.32x | N/A |
| 2025 | $75.68 Million | $104.02 Million | -$137.42 Million | 0.73x | N/A |
Competitor Companies of SEZI by Market Capitalization
Companies near Senzime AB in the global market cap rankings as of March 19, 2026.
Key companies related to Senzime AB by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #78 globally with a market cap of $191.37 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #154 globally with a market cap of $121.03 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #168 globally with a market cap of $113.17 Billion USD.
- Boston Scientific Corp (NYSE:BSX): Ranked #185 globally with a market cap of $105.26 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #78 | Abbott Laboratories | NYSE:ABT | $191.37 Billion | $110.71 |
| #154 | Stryker Corporation | NYSE:SYK | $121.03 Billion | $349.11 |
| #168 | Medtronic PLC | NYSE:MDT | $113.17 Billion | $88.44 |
| #185 | Boston Scientific Corp | NYSE:BSX | $105.26 Billion | $71.20 |
Senzime AB Historical Marketcap From 2015 to 2026
Between 2015 and today, Senzime AB's market cap moved from $53.44 Million to $ 61.10 Million, with a yearly change of 0.78%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr61.10 Million | -19.26% |
| 2025 | Skr75.68 Million | -1.82% |
| 2024 | Skr77.08 Million | -25.98% |
| 2023 | Skr104.13 Million | -30.82% |
| 2022 | Skr150.51 Million | -52.89% |
| 2021 | Skr319.53 Million | -5.00% |
| 2020 | Skr336.34 Million | +31.87% |
| 2019 | Skr255.06 Million | +142.67% |
| 2018 | Skr105.11 Million | +5.63% |
| 2017 | Skr99.50 Million | +7.20% |
| 2016 | Skr92.82 Million | +73.70% |
| 2015 | Skr53.44 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Senzime AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $61.10 Million USD |
| MoneyControl | $61.10 Million USD |
| MarketWatch | $61.10 Million USD |
| marketcap.company | $61.10 Million USD |
| Reuters | $61.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.